Floatz Rating
CC42/100
Confidence
Indicative
Sponsor
Yazeed Sawalha
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
27Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04635683CT.gov Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · MALT Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ublituximab (this asset) | Yazeed Sawalha | P1 | CC · 42 |
| Cyclophosphamide | SWOG Cancer Research Network | P2 | BBB |
| Rituximab | City of Hope Medical Center | P3 | BBB |
| Dexasone | Izidore Lossos, MD | P2 | BBB |
| Fludarabine | UNC Lineberger Comprehensive Cancer Center | P2 | BB |
| Etoposide | Fred Hutchinson Cancer Center | P2 | BB |
| Vincristine Sulfate | SWOG Cancer Research Network | P2 | BB |
| Adriamycin | SWOG Cancer Research Network | P2 | BB |
| Obinutuzumab | University of Washington | P2 | BB |
+42 more in the MALT Lymphoma cohort
Other indications for Ublituximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Relapsing-Remitting Multiple Sclerosis | — | P4 | BB · 66 |
| Marginal Zone Lymphoma | — | P2/3 | B · 57 |
| Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | — | P3 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ublituximab in MALT Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ublituximab-malt-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →